The estimated Net Worth of Marion Mc Court is at least $29.8 Milion dollars as of 3 September 2024. Ms. Court owns over 1,000 units of Regeneron Pharmaceuticals stock worth over $15,901,540 and over the last 8 years she sold REGN stock worth over $3,642,355. In addition, she makes $10,224,700 as Senior Vice President - Commercial at Regeneron Pharmaceuticals.
Marion has made over 46 trades of the Regeneron Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 1,000 units of REGN stock worth $381,400 on 3 September 2024.
The largest trade she's ever made was exercising 2,000 units of Regeneron Pharmaceuticals stock on 20 August 2020 worth over $685,860. On average, Marion trades about 596 units every 22 days since 2017. As of 3 September 2024 she still owns at least 13,931 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Ms. Court stock trades at the bottom of the page.
Marion McCourt serves as Senior Vice President - Commercial of the Company. From April 2017 until joining the Company, Ms. McCourt served as the Principal Operating Officer and the Chief Operating Officer and President of Axovant Sciences, Inc. Ms. McCourt previously served as chief operating officer of Medivation, Inc. from February 2016 until its acquisition by Pfizer Inc. in September 2016. Previously, Ms. McCourt worked at Amgen Inc., where she most recently served as a Vice President in U.S. Commercial Operations from February 2014 to January 2016. From May 2013 to January 2014, Ms. McCourt served as Vice President and General Manager at Amgen where she was responsible for the bone health and primary care business unit. From 2012 to 2013, she was Chief Operating Officer for AstraZeneca U.S., a division of AstraZeneca plc. Her responsibilities included oversight and leadership of all U.S. commercial functions, including medical affairs, business development, finance, human resources, legal, operations, and corporate affairs. During her 12-year tenure at AstraZeneca, Ms. McCourt was President and Chief Executive Officer of AstraZeneca Canada Inc. from 2011 to 2012 and also held various other roles at AstraZeneca Pharmaceuticals LP, a subsidiary of AstraZeneca plc. Ms. McCourt received her B.S. in Biology from Lafayette College.
As the Senior Vice President - Commercial of Regeneron Pharmaceuticals, the total compensation of Marion McCourt at Regeneron Pharmaceuticals is $10,224,700. There are 3 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
Marion McCourt is 60, she's been the Senior Vice President - Commercial of Regeneron Pharmaceuticals since 2018. There are 14 older and 7 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis oraz Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: